The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2005 Sep 10

PMID 16151040

Citations 147

Authors

Svetlana Gelperina

Kevin Kisich

Michael D Iseman

Leonid Heifets

Affiliations

Soon will be listed here.

Abstract

Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. This article highlights some of the issues of nanotechnology relevant to the anti-TB drugs.

Citing Articles

Development of a general anti-viral therapeutic using cholestosome technology to exploit inhibition of intracellular viral production.

Mielnicki L, Hughes J, Irving M, McCourt M Biochem Biophys Rep. 2025; 41:101922.

PMID: 39926208 PMC: 11803885. DOI: 10.1016/j.bbrep.2025.101922.

Synthesis and evaluation of amyloid beta peptide/Ruthenium III-based complex drugs as drug delivery and anticancer activity.

Senthil R Toxicol Rep. 2024; 13:101778.

PMID: 39497760 PMC: 11532921. DOI: 10.1016/j.toxrep.2024.101778.

Enhancing biodegradable smart food packaging: Fungal-synthesized nanoparticles for stabilizing biopolymers.

Rezghi Rami M, Forouzandehdel S, Aalizadeh F Heliyon. 2024; 10(18):e37692.

PMID: 39315154 PMC: 11417270. DOI: 10.1016/j.heliyon.2024.e37692.

Advances in nucleic acid delivery strategies for diabetic wound therapy.

Sarthi S, Bhardwaj H, Jangde R J Clin Transl Endocrinol. 2024; 37:100366.

PMID: 39286540 PMC: 11404062. DOI: 10.1016/j.jcte.2024.100366.

Improving glioma drug delivery: A multifaceted approach for glioma drug development.

Yonk M, Lim M, Thompson C, Tora M, Lakhina Y, Du Y Pharmacol Res. 2024; 208:107390.

PMID: 39233056 PMC: 11440560. DOI: 10.1016/j.phrs.2024.107390.

References

Schmidt C, Bodmeier R . Incorporation of polymeric nanoparticles into solid dosage forms. J Control Release. 1999; 57(2):115-25. DOI: 10.1016/s0168-3659(98)00108-4. View

Wissing S, Kayser O, Muller R . Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004; 56(9):1257-72. DOI: 10.1016/j.addr.2003.12.002. View

Sharma A, Pandey R, Sharma S, Khuller G . Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents. 2004; 24(6):599-604. DOI: 10.1016/j.ijantimicag.2004.07.010. View

Bala I, Hariharan S, Kumar M . PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2005; 21(5):387-422. DOI: 10.1615/critrevtherdrugcarriersyst.v21.i5.20. View

Salem I, Flasher D, Duzgunes N . Liposome-encapsulated antibiotics. Methods Enzymol. 2005; 391:261-91. DOI: 10.1016/S0076-6879(05)91015-X. View

Pandey R, Khuller G . Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother. 2005; 55(4):430-5. DOI: 10.1093/jac/dki027. View

Pandey R, Khuller G . Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb). 2005; 85(4):227-34. DOI: 10.1016/j.tube.2004.11.003. View

Barrow E, Winchester G, Staas J, Quenelle D, Barrow W . Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother. 1998; 42(10):2682-9. PMC: 105919. DOI: 10.1128/AAC.42.10.2682. View

Peters K, Leitzke S, Diederichs J, Borner K, Hahn H, Muller R . Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000; 45(1):77-83. DOI: 10.1093/jac/45.1.77. View

10.

Andremont A, Couvreur P . Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents. 2000; 13(3):155-68. DOI: 10.1016/s0924-8579(99)00121-1. View

11.

Soppimath K, Aminabhavi T, Kulkarni A, Rudzinski W . Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001; 70(1-2):1-20. DOI: 10.1016/s0168-3659(00)00339-4. View

12.

Moghimi S, Hunter A, Murray J . Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001; 53(2):283-318. View

13.

Dutt M, Khuller G . Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother. 2001; 47(6):829-35. DOI: 10.1093/jac/47.6.829. View

14.

Florence A, Hussain N . Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev. 2001; 50 Suppl 1:S69-89. DOI: 10.1016/s0169-409x(01)00184-3. View

15.

Ain Q, Sharma S, Garg S, Khuller G . Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int J Pharm. 2002; 239(1-2):37-46. DOI: 10.1016/s0378-5173(02)00034-0. View

16.

Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C . Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst. 2002; 19(2):99-134. DOI: 10.1615/critrevtherdrugcarriersyst.v19.i2.10. View

17.

Tsapis N, Bennett D, Jackson B, Weitz D, Edwards D . Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A. 2002; 99(19):12001-5. PMC: 129387. DOI: 10.1073/pnas.182233999. View

18.

Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P . Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev. 2003; 55(4):519-48. DOI: 10.1016/s0169-409x(03)00041-3. View

19.

Kayser O, Olbrich C, Croft S, Kiderlen A . Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs. Parasitol Res. 2003; 90 Suppl 2:S63-70. DOI: 10.1007/s00436-002-0769-2. View

20.

Pandey R, Zahoor A, Sharma S, Khuller G . Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb). 2003; 83(6):373-8. DOI: 10.1016/j.tube.2003.07.001. View